The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have awarded Cue Health $481m to produce and deploy six million point-of-care molecular COVID-19 tests by March 2021.
Cue’s COVID-19 test received an emergency use authorization from the US Food and Drug Administration in June. The test is indicated for the qualitative detection of ribonucleic acid (RNA)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?